Unveiling the Hidden Role of SNRPB2 in HCC: A Promising Target for Therapy

Author:

Guo Jiaxing1,Li Lingshu1,Wang Haiyan2,Gao Zhenqin1,Shen Chanjuan1,Yan Bokang1

Affiliation:

1. Central South University

2. Kunming Medical University

Abstract

Abstract Background: SNRPB2, a spliceosome component, is well known to participate in the pre-splicing of mRNA and plays a crucial role in the progression of several cancers. However, its precise effect on HCC remains unexplored. Methods: Bioinformatics analysis was carried out using TCGA, GTEx, GEO, HPA, CPTAC, Kaplan-Meier plotter, RNAactDrug, and R Studio.The level of SNRPB2 expression in HCC was validated via RT-qPCR, western blot, and IHC. Functional experiments, including CCK8, transwell, and colony formation assays, as well as nude mouse xenograft model, were employed for the purpose of in vitro and in vivo validation. IHC, CCK8, colony formation assays, and measurements of GSH, lipid ROS, and ferrous iron were performed to evaluate the impact of SNRPB2 on the ferroptosis of HCC cells. Databases including miRDB, miRWalk, Targetscan, miRabel, CancerMIRNome, and ENCORI, correlation analysis, RT-qPCR, and luciferase reporter assays were employed to identify the ceRNA regulatory axis of SNRPB2. Sorafenib resistant HepG2 cell line was developed to examine the effect of SNRPB2 on sorafenib resistance. Results: Here, we demonstrate that high level of SNRPB2 is significantly associated with poor outcomes in HCC patients. Additionally, inhibiting SNRPB2 may accelerate ferroptosis, thereby suppressing HCC tumor development. Moreover, SNRPB2 is regulated by the SNHG4/miR-204-5p axis, and increased SNHG4 could reverse the effect of SNRPB2 knockdown. Finally, SNRPB2 deficiency increases the sorafenib sensitivity of HCC cells. Conclusion: Conclusively, our study uncovers the previously unknown role of SNRPB2 in HCC, reveals the related ceRNA regulatory axis of SNRPB2, and identifies a novel ferroptosis regulating protein, suggesting SNRPB2 appears to be a promising target for HCC therapy.

Publisher

Research Square Platform LLC

Reference45 articles.

1. Cancer statistics, 2022 [J];SIEGEL RL;CA: a cancer journal for clinicians,2022

2. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries [J];SUNG H;CA: a cancer journal for clinicians,2021

3. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy [J];SINGAL A G, KANWAL F;Nature reviews Clinical oncology,2023

4. Management of Hepatocellular Carcinoma: A Review [J];BROWN Z J;JAMA surgery,2023

5. Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial [J];KIM T H;Journal of hepatology,2021

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3